SCHEMBL4521715

SCHEMBL4521715

CCOC(=O)C(Cc1cnc2ccccc2n1)(C(=O)OCC)N1C(=O)c2ccccc2C1=O

nearest known ligand 0.53

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CYP1A2 P05177 1/20 0.53
CYP2C9 P11712 1/20 0.53
HIF1A Q16665 1/20 0.53
ALDH1A1 P00352 7/20 0.44
KDM4E B2RXH2 4/20 0.44
SMN1; SMN2 Q16637 3/20 0.44
NPC1 O15118 3/20 0.42
RAB9A P51151 3/20 0.42
MEN1 O00255 3/20 0.42
KMT2A Q03164 3/20 0.42
CASP3 P42574 1/20 0.42
SENP7 Q9BQF6 1/20 0.42
MAPT P10636 5/20 0.39
ABCB1 P08183 1/20 0.39
HTT P42858 1/20 0.39
ABCG2 Q9UNQ0 1/20 0.39
PDE10A Q9Y233 1/20 0.38
L3MBTL1 Q9Y468 2/20 0.37
GABRP O00591 1/20 0.37
GABRD O14764 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL12385396 0.77 ALDH1A1 (0.50) ALDH1A1SMN1; SMN2NPC1RAB9AMEN1
SCHEMBL31424950 0.76 L3MBTL1 (0.45) ALDH1A1KDM4ESMN1; SMN2MEN1KMT2A
SCHEMBL4508499 0.74 ALDH1A1 (0.60) CYP1A2CYP2C9HIF1AALDH1A1KDM4E
SCHEMBL4535421 0.71 CYP1A2 (0.50) CYP1A2CYP2C9HIF1AALDH1A1KDM4E
SCHEMBL8837596 0.71 ALDH1A1 (0.42) ALDH1A1KDM4ESMN1; SMN2MEN1KMT2A
SCHEMBL25412903 0.70 CYP1A2 (0.64) CYP1A2CYP2C9HIF1AALDH1A1KDM4E
SCHEMBL15599302 0.70 CYP1A2 (1.00) CYP1A2CYP2C9HIF1AALDH1A1KDM4E
SCHEMBL4529374 0.69 CYP1A2 (0.50) CYP1A2CYP2C9HIF1AALDH1A1KDM4E
SCHEMBL9043569 0.68 CYP1A2 (0.61) CYP1A2CYP2C9HIF1AALDH1A1KDM4E
SCHEMBL11748680 0.68 ALDH1A1 (0.39) ALDH1A1KDM4ESMN1; SMN2MEN1KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7626022-B2 Racemic mixtures; oxidation; cyclization; crystallization CHIRACON GMBH (DE) 2009-12-01 US claimed
US-20050080263-A1 Method for producing ss-heteroaryl-alpha-alanine compounds using 2-amino-2-(heteroarylmethyl) carboxylic acid compounds CHIRACON GMBH (DE) 2005-04-14 US claimed
US-7626022-B2 Racemic mixtures; oxidation; cyclization; crystallization CHIRACON GMBH (DE) 2009-12-01 US disclosed
US-20050080263-A1 Method for producing ss-heteroaryl-alpha-alanine compounds using 2-amino-2-(heteroarylmethyl) carboxylic acid compounds CHIRACON GMBH (DE) 2005-04-14 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050080263-A1 Method for producing ss-heteroaryl-alpha-alanine compounds using 2-amino-2-(heteroarylmethyl) carboxylic acid compounds AAAS, ASNS, AADAT CYP1A2 95/4885CYP2C9 120/4885HIF1A 3789/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.